Clinical Translation of 18F-Labeled Hydroxyphenethylguanidines
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to perform first-in-human PET imaging studies of two new cardiac
sympathetic nerve imaging agents, 4-[18F]fluoro-meta-hydroxyphenethylguanidine ([18F]4F-MHPG)
and 3-[18F]fluoro-para-hydroxyphenethylguanidine ([18F]3F-PHPG).